RecruitingNot ApplicableNCT05151562

Music Therapy for Patients With Alzheimer's Disease

Music Therapy for Autobiographical Memory and Neuropsychiatric Symptoms in Alzheimer Disease

Sponsor

Johns Hopkins University

Enrollment

60 participants

Start Date

Jul 18, 2022

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease Mild Cognitive Impairment

Summary

This study is designed to assess the feasibility that individualized reminiscence-based virtual music therapy sessions can enhance autobiographical memory, mood, and cognition in patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD). 60 patients with MCI or mild dementia due to AD will receive two 30 minutes reminiscence-targeted virtual music therapy interventions per week for 8 weeks (a total of 16 sessions). Participants' (or supported by the study partner) self-reported and measurable outcomes including cognitive, anxiety, quality of life, and autobiographical memory will be assessed before and after the 8-week course of treatment. Blood-oxygenation level-dependent (BOLD) in functional magnetic resonance imaging (fMRI) will also be also measured before and after the 8-week course of treatment.

Eligibility

Min Age: 18 YearsMax Age: 89 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether music therapy can improve memory and brain function in people with mild cognitive impairment or early Alzheimer's disease. The study also uses brain imaging (MRI) to see if music therapy causes measurable changes in the brain. **You may be eligible if...** - You are between 18 and 89 years old - You have mild cognitive impairment or early Alzheimer's disease, based on a standard memory test (MoCA score of 17–25) **You may NOT be eligible if...** - You have had a head injury or concussion with loss of consciousness for more than 2 minutes - You have claustrophobia (fear of enclosed spaces) that would prevent you from having an MRI - You have a medical device incompatible with MRI (such as a pacemaker, cochlear implant, or certain metal implants) - You have worked as a metal worker or have certain metallic objects in your body Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALVirtual Music Therapy

Each study participant will receive two 30-minute live synchronous virtual music therapy sessions per week for a period of 8 weeks to be delivered by a board-certified music therapist (using Zoom as a primary platform). These individualized therapeutic encounters will use music that is personally meaningful and familiar to the participant and the participant's loved ones to facilitate reminiscence. Decision-making processes made by the music therapist will reflect a flexible session structure and series of intervention choices contingent on each participant's cultural identity, expressive and receptive communication, fine and gross motor ability, affect, orientation to time and place, and personal preferences on any given day.

Locations(1)

Johns Hopkins School of Medicine

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05151562

Related Trials

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT071696301 location

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

NCT0684732135 locations

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787288 locations

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

NCT07011745140 locations

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

NCT07011732157 locations